TNFSF10 and colon carcinoma: It is clear that blocking TRAIL function significantly decreased CTL-mediated tumor rejection efficacy (p = 0.03)(Fig. 7B), suggesting that tumor-specific CTLs at least partially use TRAIL to suppress colon carcinoma development in vivo.